You are here:

Category: 6.1 Drugs used in diabetes

Name SMC ID No Manufacturer Status Sub. Type
 
albiglutide (Eperzan) 1024/15 GlaxoSmithKline UK Ltd Restricted Full submission
alogliptin (Vipidia) 937/14 Takeda UK Ltd Not Recommended Full submission
alogliptin (Vipidia) 937/14 Takeda UK Ltd Restricted Resubmission
alogliptin plus metformin (Vipdomet) 998/14 Takeda UK Ltd Restricted Abbreviated Submission
Biphasic insulin aspart 30 (Novomix 30®) 06/02 Novo Nordisk Ltd Not Recommended Full submission
Biphasic insulin aspart 30 (NovoMix 30®) 06/02 Novo Nordisk Ltd Accepted Resubmission
canagliflozin (Invokana®) 963/14 Janssen-Cilag Ltd Superseded Full submission
canagliflozin plus metformin (Vokanamet) 1019/14 Janssen-Cilag Ltd Restricted Abbreviated Submission
dapagliflozin (Forxiga) 799/12 Bristol-Myers Squibb Pharmaceuticals Ltd Restricted Full submission
dapagliflozin (Forxiga) 799/12 AstraZeneca UK Ltd Restricted Resubmission
dapagliflozin (Forxiga) 799/12 AstraZeneca UK Ltd Superseded Resubmission
dapagliflozin + metformin (Xigduo) 983/14 AstraZeneca UK Ltd Restricted Abbreviated Submission
dulaglutide (Trulicity) 1110/15 Eli Lilly and Company Ltd Restricted Full submission
empagliflozin (Jardiance) 993/14 Boehringer Ingelheim Ltd Superseded Full submission
empagliflozin/metformin (Synjardy) 1092/15 Boehringer Ingelheim Ltd Restricted Abbreviated Submission
exenatide (Bydureon) 748/11 Eli Lilly and Company Ltd Restricted Full submission
exenatide (Byetta) 684/11 Eli Lilly and Company Ltd Restricted Full submission
exenatide (Byetta) 785/12 Lilly UK Accepted Full submission
exenatide 5 or 10 micrograms, solution for injection, prefilled pen (Byetta) 376/07 Eli Lilly and Company Ltd Restricted Full submission
inhaled insulin, 1mg and 3mg inhalation powder (Exubera) 254/06 Pfizer Ltd Withdrawn Full submission
insulin aspart (Fiasp) 1227/17 Novo Nordisk Ltd Accepted Abbreviated Submission
insulin degludec (Tresiba) 856/13 Novo Nordisk Ltd Accepted Resubmission
insulin degludec (Tresiba) 856/13 Novo Nordisk Ltd Not Recommended Resubmission
insulin degludec (Tresiba) 1060/15 Novo Nordisk Ltd Not Recommended Non submission
insulin degludec/liraglutide (Xultophy) 1088/15 Novo Nordisk Ltd Restricted Full submission
insulin detemir (Levemir) 780/12 Novo Nordisk Ltd Restricted Abbreviated Submission
insulin detemir (Levemir) 1126/16 Novo Nordisk Ltd Restricted Abbreviated Submission
Insulin detemir (Levemir®) 110/04 Novo Nordisk Ltd Restricted Full submission
Insulin detemir (Levemir®) 138/04 Novo Nordisk Ltd Restricted Abbreviated Submission
insulin detemir, 100 U/ml solution for injection via InnoLet device (Levemir in InnoLet) 393/07 Novo Nordisk Ltd Restricted Abbreviated Submission
insulin glargine (Lantus Solostar) 456/08 Sanofi-Aventis Restricted Abbreviated Submission
insulin glargine (Lantus) 860/13 Sanofi-Aventis Restricted Abbreviated Submission
Insulin glargine (Lantus®) 11/02 Aventis Restricted Full submission
insulin glargine (Toujeo) 1078/15 Sanofi-Aventis Restricted Abbreviated Submission
insulin glulisine (Apidra Solostar) 457/08 Sanofi-Aventis Restricted Abbreviated Submission
Insulin glulisine (Apidra) 512/08 Sanofi-Aventis Restricted Abbreviated Submission
insulin glulisine for subcutaneous injection 100 units/ml (Apidra) 298/06 Sanofi-Aventis Restricted Full submission
insulin lispro (Humalog KwikPen) 508/08 MSD Accepted Abbreviated Submission
insulin lispro (Humalog Mix25, Mix50 KwikPen) 509/08 MSD Accepted Abbreviated Submission
linagliptin (Trajenta) 850/13 Boehringer Ingelheim Ltd Restricted Full submission
linagliptin (Trajenta) 850/13 Boehringer Ingelheim Ltd Accepted Resubmission
linagliptin (Trajenta) 746/11 Boehringer Ingelheim Ltd Restricted Full submission
linagliptin + metformin (Jentadueto) 1057/15 Boehringer Ingelheim Ltd Restricted Abbreviated Submission
linagliptin+metformin (Jentadueto) 841/13 Boehringer Ingelheim Ltd Restricted Abbreviated Submission
liraglutide (Saxenda) 1247/17 Novo Nordisk Ltd Not Recommended Non submission
liraglutide (Victoza) 1044/15 Novo Nordisk Ltd Accepted Full submission
liraglutide (Victoza) 585/09 Novo Nordisk Ltd Restricted Full submission
liraglutide (Victoza) 1192/16 Novo Nordisk Ltd Not Recommended Non submission
lixisenatide (Lyxumia) 903/13 Sanofi-Aventis Restricted Full submission
metformin (Glucophage SR) 148/04 Merck Serono Ltd Restricted Resubmission
Metformin hydrochloride (Glucophage SR®) 148/04 Merck Serono Ltd Not Recommended Resubmission
Metformin hydrochloride (Glucophage SR®) 148/04 Merck Serono Ltd Not Recommended Full submission
metformin hydrochloride (Glucophage) 500mg/1000mg Powder for Solution 610/10 Merck Serono Ltd Abbreviated Submission
midodrine hydrochloride (Bramox) 1094/15 Brancaster Pharma Limited Accepted Abbreviated Submission
Pioglitazone (Actos®) 115/04 Takeda UK Ltd Restricted Resubmission
Pioglitazone (Actos®) 115/04 Takeda UK Ltd Not Recommended Full submission
pioglitazone 15mg, 30mg and 45mg tablets (Actos) 399/07 Takeda UK Ltd Accepted Full submission
pioglitazone 15mg, 30mg and 45mg tablets (Actos® triple therapy) 354/07 Takeda UK Ltd Restricted Full submission
Pioglitazone 15mg/metformin 850mg hydrochloride (Competact) 252/06 Takeda UK Ltd Restricted Abbreviated Submission
Rosiglitazone (Avandia®) 91/04 GlaxoSmithKline UK Ltd Withdrawn Resubmission
Rosiglitazone (Avandia®) 91/04 GlaxoSmithKline UK Ltd Withdrawn Full submission
Rosiglitazone maleate (Avandia Triple Therapy®) 181/05 GlaxoSmithKline UK Ltd Withdrawn Abbreviated Submission
Rosiglitazone maleate/metformin hydrochloride (Avandamet®) 140/04 GlaxoSmithKline UK Ltd Withdrawn Abbreviated Submission
rosiglitazone/metformin 2mg/500mg, 2mg/1g, 4mg/1g (Avandamet) 281/06 GlaxoSmithKline UK Ltd Withdrawn Abbreviated Submission
saxagliptin (Onglyza) 772/12 AstraZeneca UK Ltd Not Recommended Non submission
saxagliptin (Onglyza) 772/12 AstraZeneca UK Ltd Accepted Full submission
saxagliptin (Onglyza) 603/10 Bristol-Myers Squibb Pharmaceuticals Ltd Restricted Full submission
saxagliptin (Onglyza) 918/13 Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca Restricted Full submission
saxagliptin + metformin (Komboglyze) 870/13 Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca Restricted Abbreviated Submission
saxagliptin metformin (Kombogylze) 929/13 Bristol-Myers Squibb Pharmaceuticals Ltd Accepted Abbreviated Submission
sitagliptin (Januvia) 408/07 MSD Restricted Full submission
sitagliptin (Januvia) 505/08 MSD Accepted Full submission
sitagliptin (Januvia) 1083/15 MSD Accepted Full submission
sitagliptin (Januvia) monotherapy 607/10 MSD Restricted Full submission
sitagliptin plus metformin (Janumet 50/1000) 627/10 MSD Accepted Abbreviated Submission
sitagliptin/metformin (Janumet) 492/08 MSD Restricted Abbreviated Submission
vildagliptin (Galvus) 435/07 Novartis Pharmaceuticals UK Ltd Restricted Full submission
vildagliptin (Galvus) 571/09 Novartis Pharmaceuticals UK Ltd Accepted Full submission
vildagliptin (Galvus) 826/12 Novartis Pharmaceuticals UK Ltd Restricted Full submission
vildagliptin (Galvus) 875/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
vildagliptin (Galvus) 875/13 Novartis Pharmaceuticals UK Ltd Restricted Full submission
vildagliptin / metformin hydrochloride (Eucreas®) 874/13 Novartis Pharmaceuticals UK Ltd Not Recommended Non submission
vildagliptin/metformin (Eucreas) 477/08 Novartis Pharmaceuticals UK Ltd Restricted Abbreviated Submission

Back